In this edition:
CheckMate7FL: biomarker results
KEYNOTE-756: pembrolizumab + chemotherapy for early-stage, high-risk, ER+/HER2− breast cancer
ALEXANDRA/IMpassion030: atezolizumab + chemotherapy for stage II/III triple-negative breast cancer
KEYNOTE-522: 5-year EFS data
KEYNOTE-522: safety analysis
KEYNOTE-522: real-world AEs
PIONEER: megestrol + letrozole for early-stage, ER+, HER2- breast cancer
KATHERINE: T-DM1 vs. trastuzumab for HER2+, early breast cancer
INAVO120: inavolisib + palbociclib + fulvestrant in PIK3CA-altered, HR+, HER2-, locally advanced/metastatic breast cancer
MONARCH 3: final OS results
HER2CLIMB-02: tucatinib + trastuzumab emtansine for previously treated, HER2+, metastatic breast cancer
Please login below to download this issue (PDF)